Abstract
Receptor imaging by means of positron emission tomography (PET) and single photon emission computerized tomography (SPECT) may non-invasively address questions that are essential to the development and the clinical application of drugs targeting receptors expressed on human malignancies : is the receptor targeting drug getting to the tumor in the required concentration, is there a heterogeneity in tumor uptake, how fast is the drug cleared from the tumor and how is the receptor targeting drug metabolized. Such information may be used to assess the efficacy of strategies that aim to improve drug penetration through tumor tissue or to select compounds based on their ability to penetrate tumor tissue, thereby increasing the therapeutic index. In addition, imaging by means of PET and SPECT with receptor targeting radiopharmaceuticals may allow for the selection of patients that may benefit from receptor targeting therapies either ab initio, in the situation where the levels of receptor expression are proportional to the level of signaling via the receptor, or through sequential imaging in the situation where the level of receptor expression is not proportional to the level of signaling via the receptor and proof of downregulation of the number of receptors is required.
Keywords: PET, SPECT, receptor imaging, targeted therapie
Current Pharmaceutical Design
Title: Growth Factor/Peptide Receptor Imaging for the Development of Targeted Therapy in Oncology
Volume: 14 Issue: 31
Author(s): Christophe Van de Wiele, Hendricus Boersma, Rudi A. Dierckx, Bart De Spiegeleer, Aren Van Waarde and Philip H. Elsinga
Affiliation:
Keywords: PET, SPECT, receptor imaging, targeted therapie
Abstract: Receptor imaging by means of positron emission tomography (PET) and single photon emission computerized tomography (SPECT) may non-invasively address questions that are essential to the development and the clinical application of drugs targeting receptors expressed on human malignancies : is the receptor targeting drug getting to the tumor in the required concentration, is there a heterogeneity in tumor uptake, how fast is the drug cleared from the tumor and how is the receptor targeting drug metabolized. Such information may be used to assess the efficacy of strategies that aim to improve drug penetration through tumor tissue or to select compounds based on their ability to penetrate tumor tissue, thereby increasing the therapeutic index. In addition, imaging by means of PET and SPECT with receptor targeting radiopharmaceuticals may allow for the selection of patients that may benefit from receptor targeting therapies either ab initio, in the situation where the levels of receptor expression are proportional to the level of signaling via the receptor, or through sequential imaging in the situation where the level of receptor expression is not proportional to the level of signaling via the receptor and proof of downregulation of the number of receptors is required.
Export Options
About this article
Cite this article as:
de Wiele Van Christophe, Boersma Hendricus, Dierckx A. Rudi, De Spiegeleer Bart, Waarde Van Aren and Elsinga H. Philip, Growth Factor/Peptide Receptor Imaging for the Development of Targeted Therapy in Oncology, Current Pharmaceutical Design 2008; 14 (31) . https://dx.doi.org/10.2174/138161208786549434
DOI https://dx.doi.org/10.2174/138161208786549434 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and In Vitro Antitumor Activity of Novel Fluorine Containing Pyrazoles and Pyrazolines
Letters in Drug Design & Discovery Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Discovery and Development of Endocannabinoid-Hydrolyzing Enzyme Inhibitors
Current Topics in Medicinal Chemistry Screening of Potential Anticancer Compounds from Sargassum wightii to Target Breast Cancer Specific HER2 Receptor using in-silico Analysis
The Natural Products Journal Selective Glucocorticoid Receptor Ligands
Medicinal Chemistry Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors
Current Drug Metabolism Outer Surface Proteins of Borrelia: Peerless Immune Evasion Tools
Current Protein & Peptide Science Recent Progress on Tumor Missile Therapy and Tumor Vascular Targeting Therapy as a New Approach
Current Vascular Pharmacology Comparison of Large Proteomic Datasets
Current Proteomics Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Unique Medicinal Properties of Withania somnifera: Phytochemical Constituents and Protein Component
Current Pharmaceutical Design P2Y Receptors in the Mammalian Nervous System: Pharmacology, Ligands and Therapeutic Potential
CNS & Neurological Disorders - Drug Targets Ghrelin: A Molecular Target for Weight Regulation, Glucose and Lipid Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates
Current Neuropharmacology Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Genetic Variation in the β2-Adrenergic Receptor: Impact on Intermediate Cardiovascular Phenotypes
Current Pharmacogenomics and Personalized Medicine Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry Organ Preservation by the Association of Chemotherapy and Radiotherapy in Invasive Bladder Cancer
Current Drug Therapy